読み込み中
NASDAQHealthcareMedical - Diagnostics & Research
最新データ
$44.02
−$1.21 · -2.68%
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
終値時点
$44.02
−$1.21 · -2.68%
時間外
$43.72
−$0.30 · -0.68%
10月12日 18:00 ET
日中の時刻はETです。市場データは遅延する場合があります。
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
日中レンジ
現在 $44.02
52週レンジ
現在 $44.02
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
37
割高
センチメント
60
まちまち
リスク
47
やや高いリスク
モメンタム
69
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
日中レンジ
現在 $44.02
52週レンジ
現在 $44.02
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.1億0.00%2.3兆 USD0.03%$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI1.04億1.05%98.74億 USD0.35%$151.4-1.54%
iShares Russell 2000 ETFIWM9546.64万0.12%787.4億 USD0.19%$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB7924.64万0.04%1853億 USD0.03%$288.16-0.46%
First Trust NYSE Arca Biotechnology Index FundFBT7187.92万2.49%28.91億 USD0.55%$263.9-0.57%
ARK Genomic Revolution ETFARKG6774.05万3.30%15.57億 USD0.75%$49.48-3.55%
ARK Innovation ETFARKK6671.28万0.97%55.62億 USD0.75%$88.02-1.79%
Vanguard Morningstar Small-Cap Growth ETFVBK4561.23万0.10%447億 USD0.05%$340.88-1.12%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBFirst Trust NYSE Arca Biotechnology Index FundFBTARK Genomic Revolution ETFARKGARK Innovation ETFARKKVanguard Morningstar Small-Cap Growth ETFVBKAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
